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 Abstract – Although there is evidence of a growing 
awareness of the problem, no official policy statements or 
regulatory guidelines on polypharmacy have been released 
up to date by Italian Health Authorities. Medication 
review, application of appropriateness criteria and 
computerized prescription support systems are all possible 
approaches in order to improve the quality of prescribing 
in older persons. More focused training courses on 
multimorbidity and polytherapy management are 
encouraged. Furthermore a multidisciplinary approach 
integrating different health care professionals (physicians, 
pharmacists, and nurses) may positively impact on 
reducing the sense of fear related to discontinue or 
substitute drugs prescribed by others; the fragmentation of 
therapy among different specialists; reducing costs; and 
improving adverse drug reaction detection and reporting. 
Aiming at achieving the individualized pharmacotherapy, 
a multidisciplinary approach starting with identification of 
patients and risk for drug-related problems, followed by 
medication review overtime and use of inappropriateness 
criteria, supported by computerized systems has been 
proposed.  
 




 Polypharmacy is the use of four or more 
medications by a patient [1]. Polypharmacy is more 
commonly observed in patients older than 65, affecting 
about 40% of not institutionalized older adults. About 
20% of adults with general learning disability are also 
exposed to polypharmacy, which is often associated with a 
decreased quality of life, and with mobility and cognitive 
disorders [2-6]. Polypharmacy also increases the risk of 
adverse drug reactions (ADR) and of drug interactions, 
and may, therefore, trigger a prescribing cascade and 
increase the costs of therapy [7].  
The global economic and financial crisis is 
negatively impacting on the Italian healthcare system, 
which is undergoing a devolution process from the central 
to regional governments that in about one third of the 
cases (mainly in the central and southern part of the 
country) are facing large financial deficits [8-9]. The risk 
of a national debt default forced the central government to 
choose fiscal policies that increase inequalities in access 
to care, deteriorate overall health indicators and welfare, 
and further sharpen existing difference in the quality of 
care between Italian regions [10]. 
Because of the current financial difficulties in 
Italy, major economic cuts in investments for preventive 
medicine, infrastructures, health information systems and 
innovation, and physical capital renewal have been 
applied. This may have negative long-term consequences 
on the attainment of important health-care targets such as 
limiting waiting lists, improving continuity of care, and 
promoting social-healthcare integration [11]. In addition, 
these resources cuts are presumably the primary reason for 
the lack in Italy of programs on polypharmacy 
management or drug adherence. 
Taking into account the aforementioned scenario, 
the present review aims to provide an evidence-based 
description of the current status of polypharmacy in older 
adults in Italy. 
 
 
II. POLYPHARMACY: MOVING FROM 
IMPORTANCE TO URGENCY 
 
 The heterogeneity in health policies among 
different Italian regions is a likely causative factor of the 
lack in Italy of key policies and procedures on 
polypharmacy management in older adults. In fact, Italy is 
characterized by a National Health System, which is 
differently designed, administered and organized at the 
regional level. Therefore, local issues on inequalities in 
health services utilization can be ascribed to the regional 
context and data extension at the national level are eagerly 
awaited. In Italy, the delivery of care is mostly hospital 
centred, with a consequent lack of resources available for 
territorial care. The latter is delivered mostly by general 
practitioners. A recent legislation has modified the 
territorial care in Italy by introducing the concept of 
primary care, and by establishing the so called Complex 
Unity for Primary Care (UCCP) as a new tool to enhance 
the integration among different healthcare professionals 
(general practitioner, clinical nurses, territorial specialists, 
obstetricians, socio-sanitary personnel) and to facilitate 
the delivery of territorial care. Beside the difficulties 
experienced by the individual regions in applying such 
model, the law does not include clinical pharmacists 
among the professionals of the UCCPs. This remains a 
missed opportunity also considering that the previous law 
no. 69/2009 acknowledged the relevance of clinical 
pharmacists by defining the role of community 
pharmacies as socio-sanitary multipurpose service centres 
which should help to tackle problems related to chronic 
clinical conditions and polypharmacy hence playing a 
complementary role with UCCP. Unfortunately, 
community pharmacies are not currently providing 
patients with “pharmaceutical” care, but only with 
dispensation of drugs. This depends on a number of 
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factors including the slow raise of political interest in 
promoting the role of pharmacists as caregivers, the 
absence of financial investments to support this kind of 
service and the poor organization and communication 
between stakeholders both at local and national level.  
 
 
III. AWARENESS OF THE SCIENTIFIC COMMUNITY 
ON POLYPHARMACY-RELATED ISSUES IN ITALY  
 
In the last decade, several studies investigated the 
quality of drug prescriptions and other polypharmacy-
related issues in older adults in Italy. The Geriatric 
working Group of the Italian Medicines Agency (AIFA), 
the national authority responsible for drug regulations in 
Italy, conducted a study on the quality of drug prescription 
in the older (65+ years of age) Italian population 
providing a representative snapshot of pharmacological 
treatment in this age group [12]. This study focused on 13 
quality indicators to measure polypharmacy, adherence to 
the treatment of chronic diseases, the occurrence of 
prescribing cascades, undertreatment, and drug-drug 
interactions. Polypharmacy was common in this age group 
and about 1.3 out of the 11.5 millions of the tested 
individuals was taking 10 or more drugs (around 11% of 
the entire cohort). The prevalence of low adherence and 
undertreatment was also quite high and it proportionally 
increased with advancing age, peaking in individuals aged 
85 years and older.  
The “Gruppo Italiano di Farmacovigilanza 
nell’Anziano” (GIFA) study was a collaborative 
pharmacosurveillance study on hospitalized patients that 
was sponsored by the Italian National Research Council 
and the Italian Society of Gerontology and Geriatrics with 
the aim of studying quality of care and problems related to 
pharmacological therapy in older adults [13]. From 1988 
to 1998 the GIFA study evaluated more than 30,000 
hospital admissions of older patients, and found that about 
3.4% of them were ADR-related. 
The “REgistro POliterapie Societa’ Italiana di 
Medicina Interna” (REPOSI) registry is a collaborative 
research project involving the Italian Society of Internal 
Medicine, the IRCSS Ca Grande Maggiore Policlinico 
Hospital Foundation of Italy and the IRCSS Istituto di 
Ricerche Farmacologiche Mario Negri of Milan [14]. The 
REPOSI registry is a network of internal Medicine and 
geriatric wards that was established in order to evaluate 
comorbid geriatric patients treated with polypharmacy. 
The specific aims of the REPOSI registry were measuring 
the prevalence of comorbidity and treatments in 
hospitalized older adults, correlating clinical 
characteristics of patients with type and number of 
diseases and treatments, and evaluating primary clinical 
outcomes at hospital discharge and adverse events during 
hospitalizations. In addition, data from REPOSI registry 
were used to evaluate the association of specific diseases 
with polypharmacy [15]. Data showed that quality of 
prescriptions in patients discharged from hospitals was 
poor, and that often elderly patients with comorbidity did 
not receive appropriate treatment for chronic diseases. 
The criteria to Assess Appropriate Medication 
Use Among Elderly Complex Patients (CRIME) research 
project was funded by the Italian Ministry of Labour, 
Health and Social Policy with the aim of assessing the 
quality of prescription in hospitalized older adults and of 
getting helpful information to improve drug prescription 
in patients with high comorbidity and complex diseases 
[16]. This observational study performed in the geriatric 
and internal medicine acute care departments of 7 Italian 
hospitals collected data from 1123 patient, including their 
socio-demographic characteristics, several indicators of 
functional capacity and cognitive status, the clinical 
diagnoses at admission, and both the drug therapy given 
in-hospital and prescribed at discharge. The CRIME study 
showed that both polypharmacy and inappropriate 
prescribing were extremely common among hospitalized 
older adults. According to the study’s criteria, more than 
50% of drug prescriptions were inappropriate and the 
prevalence of polypharmacy (defined as concomitant use 
of ≥8 drug) was about 50%. These conditions negatively 
impact on health outcomes, such as the occurrence of 
ADRs, increased length of in-hospital stay, worsening 
functional status and mortality.  
Italy accounts for the lowest number of nursing 
home (NH) beds for the elderly, although there are 
marked differences in the availability of NH beds 
throughout the regions. Few data describing the individual 
and organizational characteristics of residents in long-term 
care facilities are available. Given the absence of a 
validated methodology for routine assessment of long-
term care facilities in all Italian regions, this crucial 
information is needed for implementing regional or 
national policies.  
Recently, Comprehensive Geriatric Assessment 
was validated and implemented, and the InterRAI tool for 
the assessment of Long-Term Care Facilities (InterRAI 
LTCF) became essential for assessing characteristics of 
NH residents, including drug use, in clinical studies. The 
Services and Health for Elderly in Long-Term Care 
(SHELTER) study was a project funded by the 7th 
Framework Program of the European Union that 
translated, validated and implemented the interRAI LTCF 
across different health systems in European countries as a 
tool to assess and gather uniform information about NH 
residents [17]. The SHELTER study was conducted from 
2009 to 2011 in 7 EU countries (Czech Republic, 
England, Finland, France, Germany, Italy and the 
Netherlands) and one non-EU country (Israel). 
Additionally, the “Un Link Informatico Sui Servizi 
Sanitari Esistenti per L’anziano” (ULISSE) study 
implemented the interRAI LTCF in 31 NHs in Italy [18]. 
Although these studies were not specifically 
designed to assess drug use, SHELTER showed that 
polypharmacy was extremely common in NH residents, 
and that it was associated with negative outcomes. This 
held especially true in residents with limited life 
expectancy. Notably, in these patients, clinical benefits 
derived from the use of multiple drugs were negligible and 
did not mitigate the risk of iatrogenic illness. The negative 
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effects of polypharmacy were also confirmed in the 
ULISSE study, which showed that the concomitant use of 
multiple drugs was associated with an increased risk of 
hospitalization. 
 Although the available data suggests that 
polypharmacy could be efficiently tackled, public health 
strategies on this specific issue are still missing. 
 
 
IV. CHANGE MANAGEMENT STRATEGIES 
 
Therapeutic Review and Medication 
Reconciliation are two mandatory steps both in drug 
prescribing and in drug de-prescribing (tapering or 
stopping drugs) processes. In fact, the same good practices 
and principles should be applied when a drug therapy is 
initiated and when it is time that it is discontinued [19].  
Therapeutic review is a systematic process in 
which physicians collect information on all conventional 
and non-conventional drugs taken by a specific patient, 
and compare them with those recommended by 
guidelines. At the time of therapeutic review potential 
drug-related problems in patient therapeutic regimen are 
also identified. The final aim of therapeutic review is to 
verify whether patient’s current medications are 
appropriate and have a favourable benefit-to-risk ratio. 
Usually, medication review is a multidisciplinary process 
involving not only the prescribing physician, but also the 
clinical pharmacist and other health care professionals 
such as clinical nurses. Thanks to the contribution of these 
diverse professional benefits and risks of the drug 
treatment in place are evaluated under multiple 
perspectives and possible solutions for potential drug-
related problems are identified and their feasibility and 
applicability is critically examined [20]. Additional 
benefits of therapeutic review include an increase in 
patient safety due to reduced discrepancies, improved 
prescription appropriateness and reduced ADRs. 
Medication reconciliation is the process of 
avoiding inadvertent inconsistencies within a patient’s 
drug regimen, which can occur during transitions in 
different setting of care. These reviews are conducted to 
ensure that the patient is still on the appropriate drug 
therapy regimen after experiencing care transitions [21]. 
The role of medication reconciliation as a routinal and 
standardized step, especially in the transitional care 
process, is supported by health care agencies at both 
European level and the national level. For example, both 
the Joint Commission and the Italian Ministry of Health 
have acknowledged medication reconciliation as an 
important tool to prevent medical errors and drug-related 
problems [22]. Medication reconciliation is essential for 
the continuity of patient’s treatment across different 
hospitals, hospital wards and specialists, and when the 
patient returns to primary care after being discharged from 
the hospital. This does not mean, however, that the drug 
regimen has to be indefinitely kept unchanged. Indeed, 
medication reviews mainly checks for inadvertent or 
erronoeus changes but drug prescription should be viewed 
as a dynamic process in which drug benefits or harms are 
continously checked, managed and assessed in a 
multidisciplinar and integrated longitudinal process. 
Moreover, the approach should incorporate 
implementation of inappropriate drug criteria and 
computer-based prescribing systems. 
Still, specific tools to assess quality of 
prescribing and to avoid inappropriate drug prescriptions 
have not been yet implemented. During the last few 
decades, much effort has been produced to improve the 
quality of drug prescription in older adults, and several 
criteria have been developed [23-26]. However, the lack 
of data integration and interoperability of ICT solutions in 
healthcare is a national issue in Italy that complicates their 
widespread application. Indeed, in 2016, Italy is still 
lacking a nationwide e-health record. In addition, pilot 
studies do not translate in regulatory actions of the 
National Health System. 
Clinical practice guidelines (CPGs) are an 
additional tool that could help change management 
strategies. CGPs are condition-specific recommandations 
that are developed to support physicians in the decision-
making processes. The movement towards evidence-based 
medicine quickly widespread over the past few years, 
stimulated by clinicians, politicians and decision-makers 
concerned about quality, consistency and costs. The 
guidelines content, based on a systematic review of 
clinical studies, have been shown to be effective in 
supporting improvements in quality and consistency in 
healthcare. In Italy, the National System for Guidelines 
[Sistema Nazionale Linee Guida (SNLG)] give clinical 
recommendations based on the most updated researches 
[27]. Unfortunately, to date, no specific tools, guidelines 
or policies for polipharmacy management and monitoring 
in Italy are available. The importance of such tools is of 
paramount importance in the light of the multiple drug 
therapies also including hormones in some patient 




V. AN ICT-BASED MODEL TO TACKLE 
POLYPHARMACY RELATED ISSUES 
 
Every single patient needs a comprehensive 
assessment in order to give him a personalized therapy 
that balances benefits and harms and takes full account of 
his priorities and preferences. During this patient-specific 
assessment medical doctors have to evaluate the numerous 
factors that can influence the efficacy of the drugs that 
they are going to prescribe and that are not covered in 
disease-specific guidelines. In older patients, these factors 
could include, for instance, cognitive and functional 
impairment, and the lack of social support. Because there 
are too many potential drug-drug interactions across all 
the possible combinations of the drugs used for chronic 
disease to be memorized by the average medical doctor or 
to be included in clinical practice guidelines, efficient 
computerised prescription support tools are needed to alert 
the physicians on problems potentially caused by their 
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prescriptions, helping them to improve drug prescribing 
and to reduce the risk of harmful drug interactions. 
 
Computerized Entry Order and Computerized 
Prescription Support Systems are interactive software 
systems created to assist physicians in providing the 
correct prescriptions, and ultimately avoiding drug-related 
problems. Computerized prescription support systems 
might change health care provider behaviour, improving 
physicians performance, and reducing drug-drug 
interactions and  the number of inappropriate prescriptions 
[30]. However, these methods are rarely used in 
combination with multidimensional approach tools to 
assess the complexity of older patients such as the 
Comprehensive Geriatric Assessment (CGA) tool 
although a number of studies showed that CGA is the 
gold-standard method to manage and improve the quality 
of prescriptions [31]. Preliminary data demonstrated that 
CGA, when combined with the computerized approaches, 
improves drug use and has positive effects on health 
outcomes, including a reduction in ADRs. A “global 
approach” also addressing the medical complexity of older 
adults seems, therefore, to be mandatory.  
The final goal to achieve should be to deliver a tailored 
pharmacotherapy that takes into the due account some 
critical issues, such as patients’ characteristics, life 
expectancy, preferences and priorities. Time to benefit and 
the relative effectiveness of treatment in specific clinical 
conditions should also be considered. Facilitators and 
barriers for the implementation of such a polypharmacy 
and adherence review program are summarized in Tables 
1 and 2. 
We propose that to achieve the aforementioned 
goal of a tailored pharmacotherapy a multifaceted 
intervention should be implemented that starts from the 
idetification of patients at risk of drug-related problems 
(Figure 1). Risk scores for ADRs are currently available in 
the literature and are easily applicable in everyday clinical 
practice. In addition, the medical and/or pharmaceutical 
personnel in charge of the patient should perform 
medication review and medication reconciliation, at 
regular intervals or at any time when she/he changes 
setting.  
Finally, this multifaceted intervention has to be 
contextualized in the global evaluation of older adults 
performed with CGA. Frailty, cognitive functioning, 
symptoms of depression and anxiety, functional status, 
motor abilities, swallowing problems, socio-economic 
status, adherence to treatments are all evaluated by the 
CGA, which, in the end, helps the prescribing physician to 
choose the best possible and most appropriate 
pharmacotherapy for a specific patient at that moment. 
Moreover, CGA may help to improve communication, 
coordination and transparency among clinicians, patients, 
caregivers and other providers of care, and it represents a 




Fig. 1. Proposed algorithm for polypharmacy management. To 
deliver the best-tailored pharmacotherapy for each single patient a 
multicomponent approach should be adopted. It starts with the 
identification of patients at risk for drug-related problems that are, then, 
followed overtime with periodic medication reviews also using drug 
inappropriateness criteria. This patient care strategy is embedded in the 





 The present review highlighted the absence in 
Italy of key policies and procedures for polypharmacy 
Table 1 - Facilitators of the implementation of polypharmacy 
and adherence review programs 
 Pilot studies specifically focused on polypharmacy and 
adherence programme should be designed and implemented to 
generate evidences on health outcomes in older adults; 
 University training courses specifically focused on 
polypharmacy and adherence programme should be 
implemented and delivered to medicine and pharmacy 
students, and to nurses; 
 Healthcare Professional Councils should support the initiatives 
related to polypharmacy and adherence review programs; 
 Pharma industries should be involved to the initiatives related 
to polypharmacy and adherence review programs; 
 GPs should be consortiated in order to reduce to workload and 
co-adjuvanted by other health care professionals such as 
pharmacists and nurses; 
 In line with other Countries, clinical pharmacist (working on 
medical wards) should be adopted as health care professional 
in Italy; 
 Dedicated in-hospital ambulatories on polypharmacy and 
adherence review;  
 Community pharmacies should be integrated to GPs for 
polypharmacy and adherence review programs; 
 Health information technology infrastructure may help to 




Table 2 - Barriers to the implementation of polypharmacy and 
adherence review programs
 Lack of clear policies; 
 Resistance to change (cultural barriers); 
 Spending review (poor resources); 
 Organizational boundaries as silos; 
 Healthcare system devolution 
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management in older adults. We propose that a 
multicomponent ICT-based approach could help 
addressing these issues and should be tested in pragmatic, 
community-dwelling randomized clinical trials. The 
effectiveness of this intervention should be evaluated not 
only with respect to the reduction of inappropriate 
polypharmacy and related-costs, to the improvement in 
the quality of prescribing or a to a decrease in the burden 
of drug-related problems, but also with respect to patient-
related outcomes and priorities, such as quality of life, 
hospitalization, emergency room admissions and 
disability. This strategy could also provide validated 
evidence regarding better treatment strategies for older 
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